A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 ? platinum resistant disease and are PARP inhibitor naive; Cohort 2 ? had at least 1 prior line of thera